UnitedHealth backs Gilead's Harvoni as preferred hepatitis C treatment
January 28, 2015 at 16:16 PM EST
Jan 28 (Reuters) - UnitedHealth Group Inc on Wednesday backed Gilead Sciences Inc's hepatitis C treatment Harvoni on its 2015 commercial drug coverage list over a new competitor, Viekira Pak from AbbVie Inc.
